{"id":5487,"date":"2026-11-14T15:05:44","date_gmt":"2026-11-14T15:05:44","guid":{"rendered":"https:\/\/xesi.net\/?p=5487"},"modified":"2026-11-14T15:05:44","modified_gmt":"2026-11-14T15:05:44","slug":"new-research-identifies-key-gene-behind-aggressive-treatment-resistant-prostate-cancer","status":"publish","type":"post","link":"https:\/\/xesi.net\/?p=5487","title":{"rendered":"New Research Identifies Key Gene Behind Aggressive, Treatment-Resistant Prostate Cancer"},"content":{"rendered":"<p>Researchers at the University of Michigan Rogel Cancer Center have identified a critical gene that acts as a driver for prostate cancer cells as they transition into more aggressive, treatment-resistant forms. This breakthrough discovery, published in the <em>Journal of Clinical Investigation<\/em>, sheds light on the mechanisms of &quot;lineage plasticity&quot;\u2014a process that allows cancer cells to shed their original identity and evade standard therapies. By identifying this gene, researchers have also pointed toward a potential, ready-to-use treatment strategy using an existing class of drugs, offering a glimmer of hope for patients who have exhausted current therapeutic options.<\/p>\n<p>Prostate cancer has long been treated by targeting the androgen receptor, a protein that acts as the primary fuel source for the growth of most prostate tumors. However, a significant subset of patients eventually develops resistance to these therapies. When this happens, the cancer often undergoes a transformation, losing its reliance on the androgen receptor and adopting an entirely different, more aggressive identity. This shift is a known clinical hurdle, often leading to poor outcomes for patients.<\/p>\n<p>&quot;Patients whose prostate tumors lose reliance on the androgen receptor do poorly,&quot; explains senior study author Joshi J. Alumkal, M.D., the Wicha Family Professor of Oncology at the University of Michigan Rogel Cancer Center. &quot;Our results suggest a therapeutic approach for patients whose tumors have undergone that shift.&quot;<\/p>\n<p>The research builds upon earlier scientific understandings of lineage plasticity, a process in which prostate cancer cells navigate a complex continuum of cellular identities. In typical prostate cancer cases, the cells are dependent on the androgen receptor, which governs their growth and behavior. However, through lineage plasticity, these cells can effectively &quot;reprogram&quot; themselves, taking on alternate identities that render androgen-directed therapies\u2014the cornerstone of prostate cancer treatment\u2014largely ineffective.<\/p>\n<p>To understand the biological triggers of this transition, the research team, led by Zhi Duan, Ph.D., performed a deep dive into the genetic factors that drive this cellular evolution. Through extensive analysis of tumor biopsies taken from patients whose cancers had already undergone this transformation, the researchers identified a standout gene: PROX1.<\/p>\n<p>The study revealed that PROX1 plays a central role in dictating cell identity in both healthy tissues and cancerous ones. As prostate cancer cells begin the transition to an alternate, more aggressive identity, the expression of the PROX1 gene increases significantly. By examining hundreds of patient tumor samples across the spectrum of lineage plasticity, the team confirmed that PROX1 serves as a reliable early marker of this dangerous transition. Specifically, they found that PROX1 is activated in two of the most difficult-to-treat subtypes of the disease: &quot;double-negative&quot; prostate cancer, which shows low androgen receptor activity, and neuroendocrine prostate cancer, which has lost expression of the receptor entirely.<\/p>\n<p>The data further demonstrated an inverse relationship between the two proteins; in patient tumor datasets, high levels of PROX1 were consistently associated with low levels of the androgen receptor. To confirm this functional link, the researchers introduced PROX1 into prostate cancer cells, which subsequently led to the shutting down of the androgen receptor. <\/p>\n<p>&quot;We think PROX1 is regulating the androgen receptor,&quot; Dr. Alumkal noted. &quot;It may be one explanation for why the androgen receptor gets turned off when tumors undergo lineage plasticity and transition away from the typical glandular prostate cancer identity.&quot;<\/p>\n<p>Having established that PROX1 acts as a driver of this resistance, the team sought to determine if the gene could be neutralized. Using genetic techniques to eliminate PROX1 expression in both double-negative and neuroendocrine prostate cancer cell models, the researchers observed that the cancer cells stopped growing and, in many cases, began to die. This result provided a crucial proof-of-concept: if they could successfully inhibit the function of PROX1 in a clinical setting, they might be able to halt the progression of these aggressive tumors.<\/p>\n<p>However, the team faced a significant hurdle: PROX1 is a transcription factor, a type of protein that functions by binding to DNA to turn genes on or off. Historically, transcription factors have been notoriously difficult to target with conventional pharmaceutical drugs, as they often lack the physical &quot;pockets&quot; or binding sites that most small-molecule drugs require to be effective. <\/p>\n<p>Undeterred, the researchers looked for a workaround by investigating the proteins that interact with PROX1. By identifying the molecular partners that &quot;keep company&quot; with the transcription factor, they hoped to find a more druggable target. Among the most frequent partners identified were histone deacetylases, commonly known as HDACs.<\/p>\n<p>&quot;We felt like this was guilt by association,&quot; Dr. Alumkal explained. &quot;We hypothesized that HDACs might cooperate with PROX1 and that targeting HDACs might be like targeting PROX1.&quot;<\/p>\n<p>This hypothesis proved promising, as HDACs are already well-understood in the field of oncology. In fact, several HDAC inhibitors have already received approval from the U.S. Food and Drug Administration for the treatment of other types of cancer. When the researchers treated PROX1-expressing prostate cancer cells with these existing HDAC inhibitors, the results were striking. The cancer cells proved highly sensitive to the treatment, which led to the depletion of the PROX1 protein. As the PROX1 levels plummeted, the tumor cells died, mirroring the effects the team had seen when they genetically silenced the gene.<\/p>\n<p>The findings suggest that the existing class of HDAC inhibitors could be repurposed to address a major clinical unmet need. Because these drugs have already passed safety trials for other conditions, they could potentially be moved into clinical trials for aggressive prostate cancer patients more rapidly than entirely new, experimental therapies.<\/p>\n<p>&quot;Our work implicates PROX1 as an important early driver away from androgen receptor dependence,&quot; Dr. Alumkal said. &quot;HDAC inhibitors can block PROX1 and reduce survival of aggressive prostate tumor models that have transitioned away from androgen receptor reliance. Our results suggest this class of drugs should be prioritized for clinical trials in patients who have aggressive prostate cancer subtypes, for which there are few treatment options.&quot;<\/p>\n<p>The study, which involved an extensive list of collaborators, including Mingchen Shi, Anbarasu Kumaraswamy, Dong Lin, and numerous others across various research institutions, highlights the power of modern genomic analysis in decoding complex disease resistance. The project was supported by significant funding from the National Institutes of Health, the U.S. Department of Defense, and several other organizations, including the Prostate Cancer Foundation and the Canadian Institutes of Health Research.<\/p>\n<p>As the scientific community continues to grapple with the mechanisms of cancer evolution, the discovery of the PROX1-HDAC axis offers a concrete pathway forward. By providing a clear biological explanation for how prostate cancer sheds its dependency on androgens and identifying an existing class of drugs capable of intervening in that process, the University of Michigan team has provided a foundation for future clinical studies that could offer new hope to patients facing the most challenging forms of this disease.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Researchers at the University of Michigan Rogel Cancer Center have identified a critical gene that acts as a driver for prostate cancer cells as they transition into more aggressive, treatment-resistant forms. This breakthrough discovery, published in the Journal of Clinical Investigation, sheds light on the mechanisms of &quot;lineage plasticity&quot;\u2014a process that allows cancer cells to [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":5486,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[650],"tags":[3611,780,1168,652,2681,451,2241,2245,678,2244,2243,651],"class_list":["post-5487","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health-and-wellness","tag-aggressive","tag-behind","tag-cancer","tag-fitness","tag-gene","tag-health","tag-identifies","tag-prostate","tag-research","tag-resistant","tag-treatment","tag-wellness"],"_links":{"self":[{"href":"https:\/\/xesi.net\/index.php?rest_route=\/wp\/v2\/posts\/5487","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/xesi.net\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/xesi.net\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/xesi.net\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/xesi.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=5487"}],"version-history":[{"count":0,"href":"https:\/\/xesi.net\/index.php?rest_route=\/wp\/v2\/posts\/5487\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/xesi.net\/index.php?rest_route=\/wp\/v2\/media\/5486"}],"wp:attachment":[{"href":"https:\/\/xesi.net\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=5487"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/xesi.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=5487"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/xesi.net\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=5487"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}